Clinical Trials Logo

Clinical Trial Summary

Behçet's Disease (BD) is a chronic, inflammatory, rheumatic disease that is characterized by mucocutaneous lesions. Promoting physical activity level is one of the major goals in the management of patients with rheumatic diseases, it is important to determine the factors affecting physical activity level and exercise barriers. The aim of this study is to investigate physical activity level and exercise barriers in patients with BD. Physical activity level, exercise barriers, disease activity, fatigue, depression, pain, sleep disorders, aerobic capacity and quality of life will be assessed using International Physical Activity Questionnaire-Short Form (IPAQ),Exercise Benefits/Barriers Scale, Behçet Disease Current Activity Form (BDCAF), Fatigue Severity Scale (FSS), Beck Depression Inventory (BDI), McGill Pain Questionnaire- Short Form (MPQ-SF), Pittsburgh Sleep Quality Index, 6 minute walk test and Behçet's Disease Quality of Life Questionnaire, respectively.


Clinical Trial Description

Behçet's Disease (BD) is a chronic, inflammatory, rheumatic disease that is characterized by mucocutaneous lesions and can be seen major organ involvement such as eyes, musculoskeletal system, gastrointestinal system and central nervous system. Gender and clinical findings effect the prognosis of the disease. Physical activity is all body movements requiring energy expenditure over basal metabolism and contraction of skeletal muscle. Promoting physical activity level is one of the major goals in the management of patients with rheumatic diseases because of negative impact of sedentary lifestyle which depends on rheumatic involvement.Impaired quality of life, aerobic capacity, respiratory function and life satisfaction, sleep disorders, depression, anxiety and fatigue are seen commonly in BD patients like the other rheumatic diseases. Because of these symptoms, it is possible and expected that BD patients have low physical activity level. Considering that regular physical activity effects survival for patients and healthy people, it is important to determine the factors affecting physical activity level and exercise barriers. The aim of this study is to investigate physical activity level and exercise barriers in patients with BD. Physical activity level, exercise barriers, disease activity, fatigue, depression, pain, sleep disorders, aerobic capacity and quality of life will be assessed using International Physical Activity Questionnaire-Short Form (IPAQ),Exercise Benefits/Barriers Scale, Behçet Disease Current Activity Form (BDCAF), Fatigue Severity Scale (FSS), Beck Depression Inventory (BDI), McGill Pain Questionnaire- Short Form (MPQ-SF), Pittsburgh Sleep Quality Index, 6 minute walk test and Behçet's Disease Quality of Life Questionnaire, respectively. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03837236
Study type Interventional
Source Gazi University
Contact Songul Baglan Yentur
Phone +90 312 216 26 12
Email songulbaglan23@hotmail.com
Status Recruiting
Phase N/A
Start date February 8, 2019
Completion date November 8, 2019

See also
  Status Clinical Trial Phase
Recruiting NCT04528082 - Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease Phase 3
Recruiting NCT04101604 - Biomarkers of Common Eye Diseases
Terminated NCT04609397 - A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet Disease Phase 2
Not yet recruiting NCT05128357 - IMPACT_BD (IMProving AdherenCe to Treatment in Behçet's Disease)
Not yet recruiting NCT04126850 - Pilot Project: The Amplicon and Metatranscriptomic Study of Intra and Extra Intestinal Microbiome in Non-infectious Uveitis Disease
Recruiting NCT05879419 - Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases Phase 4
Completed NCT03209219 - Interferon α2a Versus Cyclosporine for Refractory Behçet's Disease Uveitis Phase 3
Completed NCT04386824 - Erectile Dysfunction in Patients With Non Ocular Behçet's Disease
Completed NCT02648581 - Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behçet Disease Phase 2
Recruiting NCT06451575 - Thrombophilia and Thrombosis in Behçet's Disease
Recruiting NCT04530461 - Serologic Profile of SARS CoV2 in COVID-19 Patients With Systemic Diseases
Not yet recruiting NCT06386744 - Dusquetide for the Treatment of Behcet's Disease Phase 2
Recruiting NCT04334031 - Deployment o the Multidisciplinary Prospective Cohort Imminent N/A
Not yet recruiting NCT04105439 - Plasma Soluble Urokinase Plasminogen Activator Receptor and Behçet's Disease .
Not yet recruiting NCT05715294 - The Effect of Music on Sleep Quality in Behçet's Patients N/A
Active, not recruiting NCT06266247 - How Sirtuin Levels Change During Behçet Disease N/A
Recruiting NCT04959435 - Understanding the Role of Oral Microbiota in Behçet's Disease (BEHCETBIOT)
Recruiting NCT03803462 - Behçet's Disease Overall Damage Index